Published in Cancer Weekly, December 12th, 2006
The study - Study 44 - will be conducted at 208 centers across 23 countries worldwide, and is expected to enroll more than 930 patients. Study 44 will evaluate overall survival with vandetanib 300mg plus best supportive care (BSC) compared with placebo plus BSC in patients with advanced NSCLC, who have previously received treatment with chemotherapy and an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.